MCDA framework for orphan drugs (Wagner et al. EVIDEM-based)
This method uses a structured scoring system to evaluate orphan drugs based on multiple criteria beyond just cost and effectiveness, such as disease severity and patient impact. It helps assess the overall value of rare disease treatments and explores how that value relates to their price.
At a glance
Use when
Assessing value of orphan drugs in reimbursement or coverage decisions; when traditional cost-effectiveness analysis is inadequate due to uncertainty or rarity; facilitating multi-stakeholder discussions on drug value.
Avoid when
When robust clinical and economic data are available for standard HTA; when a rapid assessment is needed without stakeholder input; when criteria relevance is not validated for the local context.
Inputs
Nine criteria scores (1–3 scale) for each orphan drug, optionally with assigned weights; drug cost data; optionally, cost included as an attribute.
Outputs
Aggregate MCDA score per drug; correlation statistics (e.g., R²) between score and cost; visual plots of score vs. cost; sensitivity analysis results under different weightings.
How it works
A multi-criteria decision analysis (MCDA) framework based on the EVIDEM approach, adapted from Wagner et al. (2012), applies nine criteria scored from 1 to 3 to evaluate orphan drugs. Aggregate scores are calculated with optional weighting; correlation analysis is performed between these scores and average annual cost per patient to assess value-pricing alignment. The framework was tested in a 2017 study showing a strong correlation (R² = 0.79) between MCDA scores and drug cost.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Patient and Social Aspects
- Assumptions
- The nine criteria adequately represent the value dimensions of orphan drugs; a linear scoring system (1–3) is sufficient; weights reflect stakeholder preferences; value should correlate with price.
- Strengths
- Provides a structured, transparent, and comprehensive assessment of orphan drug value; allows inclusion of patient and social aspects; enables sensitivity testing via weighting; supports decision-making where traditional HTA is limited.
- Limitations
- Scoring is subjective and may lack consistency; limited validation across diverse health systems; small sample size in initial testing; potential bias in weight selection; does not replace full economic modeling.
- Also known as
- EVIDEM-based MCDA for orphan drugs, Wagner et al. MCDA framework, MCDA for orphan medicinal products
Questions this answers
- › What is the overall value of an orphan drug considering clinical, economic, and social factors?
- › How does the value of an orphan drug, as measured by multi-criteria analysis, relate to its annual cost?
- › Which non-cost criteria (e.g., disease severity, unmet need) contribute most to the value of orphan drugs?
- › Can MCDA provide a transparent and structured approach to reimbursement decisions for orphan drugs?
- › How sensitive is the value assessment to changes in criterion weights?
- › What happens to value rankings when drug cost is included as an evaluation criterion?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.